Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA5m chelators

• Published in: EJNMMI radiopharmacy and chemistry 2020-07, Vol.5 (1), p.19-19, Article 19
• Main Authors: Moon, Euy Sung, Elvas, Filipe, Vliegen, Gwendolyn, De Lombaerde, Stef, Vangestel, Christel, De Bruycker, Sven, Bracke, An, Eppard, Elisabeth, Greifenstein, Lukas, Klasen, Benedikt, Kramer, Vasko, Staelens, Steven, De Meester, Ingrid, Van der Veken, Pieter, Rösch, Frank
• Format: Article
• Language: English
• Subjects: Affinity; Breast cancer; Chelating agents; Chemistry; Colorectal carcinoma; DATA5m; DOTA; Enzymes; FAP; Fibroblast activation protein; Fibroblasts; Gallium; Gallium-68; Imaging; Medicine; Medicine & Public Health; Molecular Medicine; Nuclear Chemistry; Nuclear Medicine; Oligopeptidase; Pharmaceuticals; Pharmacotherapy; PREP; Prolyl oligopeptidase; Proteinase inhibitors; Proteins; R&D; Radioactive tracers; Radioisotopes; Radiology; Research & development; Research Article; Serine proteinase; Squaric acid; Stroma; Tumors
• ISSN: 2365-421X; 2365-421X
• DOI: 10.1186/s41181-020-00102-z

Background Fibroblast activation protein (FAP) is a proline selective serine protease that is overexpressed in tumor stroma and in lesions of many other diseases that are characterized by tissue remodeling. In 2014, a most potent FAP-inhibitor (referred to as UAMC1110) with low nanomolar FAP-affinity and high selectivity toward related enzymes such as prolyl oligopeptidase (PREP) and the dipeptidyl-peptidases (DPPs): DPP4, DPP8/9 and DPP2 were developed. This inhibitor has been adopted recently by other groups to create radiopharmaceuticals by coupling bifunctional chelator-linker systems. Here, we report squaric acid (SA) containing bifunctional DATA 5m and DOTA chelators based on UAMC1110 as pharmacophor. The novel radiopharmaceuticals DOTA.SA.FAPi and DATA 5m .SA.FAPi with their non-radioactive derivatives were characterized for in vitro inhibitory efficiency to FAP and PREP, respectively and radiochemical investigated with gallium-68. Further, first proof-of-concept in vivo animal study followed by ex vivo biodistribution were determined with [ 68 Ga]Ga-DOTA.SA.FAPi. Results [ 68 Ga]Ga-DOTA.SA.FAPi and [ 68 Ga]Ga-DATA 5m .SA.FAPi showed high complexation > 97% radiochemical yields after already 10 min and high stability over a period of 2 h. Affinity to FAP of DOTA.SA.FAPi and DATA 5m .SA.FAPi and its nat Ga and nat Lu-labeled derivatives were excellent resulting in low nanomolar IC 50 values of 0.7–1.4 nM. Additionally, all five compounds showed low affinity for the related protease PREP (high IC 50 with 1.7–8.7 μM). First proof-of-principle in vivo PET-imaging animal studies of the [ 68 Ga]Ga-DOTA.SA.FAPi precursor in a HT-29 human colorectal cancer xenograft mouse model indicated promising results with high accumulation in tumor (SUV mean of 0.75) and low background signal. Ex vivo biodistribution showed highest uptake in tumor (5.2%ID/g) at 60 min post injection with overall low uptake in healthy tissues. Conclusion In this work, novel PET radiotracers targeting fibroblast activation protein were synthesized and biochemically investigated. Critical substructures of the novel compounds are a squaramide linker unit derived from the basic motif of squaric acid, DOTA and DATA 5m bifunctional chelators and a FAP-targeting moiety. In conclusion, these new FAP-ligands appear promising, both for further research and development as well as for first human application.